tradingkey.logo

Biote Corp

BTMD
查看詳細走勢圖
2.780USD
+0.030+1.09%
收盤 12/19, 16:00美東報價延遲15分鐘
85.29M總市值
3.07本益比TTM

Biote Corp

2.780
+0.030+1.09%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.09%

5天

+2.96%

1月

+6.11%

6月

-29.80%

今年開始到現在

-55.02%

1年

-54.43%

查看詳細走勢圖

TradingKey Biote Corp股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Biote Corp當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在專業與商業服務行業排名83/156位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價5.09。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Biote Corp評分

相關信息

行業排名
83 / 156
全市場排名
218 / 4582
所屬行業
專業與商業服務

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
5.093
目標均價
+98.96%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Biote Corp亮點

亮點風險
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
業績高增長
公司營業收入穩步增長,連續3年增長19.54%
估值合理
公司最新PE估值3.07,處於3年歷史合理位
機構減倉
最新機構持股20.37M股,環比減少0.13%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉2.54K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.51

Biote Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Biote Corp簡介

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
公司代碼BTMD
公司Biote Corp
CEOChristensen (Bret)
網址https://haymakeracquisition.com/

常見問題

Biote Corp(BTMD)的當前股價是多少?

Biote Corp(BTMD)的當前股價是 2.780。

Biote Corp 的股票代碼是什麼?

Biote Corp的股票代碼是BTMD。

Biote Corp股票的52週最高點是多少?

Biote Corp股票的52週最高點是6.360。

Biote Corp股票的52週最低點是多少?

Biote Corp股票的52週最低點是2.315。

Biote Corp的市值是多少?

Biote Corp的市值是85.29M。

Biote Corp的淨利潤是多少?

Biote Corp的淨利潤為3.16M。

現在Biote Corp(BTMD)的股票是買入、持有還是賣出?

根據分析師評級,Biote Corp(BTMD)的總體評級為買入,目標價格為5.093。

Biote Corp(BTMD)股票的每股收益(EPS TTM)是多少

Biote Corp(BTMD)股票的每股收益(EPS TTM)是0.906。
KeyAI